1	Prognostic value of	nlasma IgG N-glycom	e traits in patie	ents with pulmonary
1	1 I Ognostic value of		c trans m paus	mus with pullional y

- arterial hypertension: an observational cohort study 2
- 3 **Running title**: *Plasma prognostic glycan biomarker for PAH*
- Ze-Jian Zhang, PhD^{1#}; Chao Liu, MD^{2#}; Jie-Ling Ma, MD^{2#}; Jing-Si Ma, BS³; Jia 4
- Wang, BS⁴; Ruo-Nan Li, BS³; Dan Lu, MD⁵; Yu-Ping Zhou, MD²; Tian-Yu Lian, 5
- MD¹; Si-Jin Zhang, MD⁶; Jing-Hui Li, MD⁷; Lan Wang, MD⁸; Kai Sun, MD¹; Chun-6
- Yan Cheng, MD^{6*}; Wen-Hui Wu^{8*}; and Zhi-Cheng Jing, MD^{6*} 7

Affiliations 8

- ¹State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical 9
- College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical 10
- College, Beijing 100730, China; 11
- 12 ²Department of Cardiology, State Key Laboratory of Complex Severe and Rare
- Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 13
- Sciences and Peking Union Medical College, Beijing 100730, China; 14
- 15 ³School of Pharmacy, Henan University, Kaifeng 475004, China;
- ⁴Department of Medical Laboratory, Weifang Medical University, Weifang 261053 16
- 17 China;
- ⁵Cardiac Department, Aerospace Center Hospital, Peking University Aerospace School 18
- of Clinical Medicine, Beijing 100049, China; 19
- ⁶Department of Cardiology, Guangdong Institute of Cardiovascular Diseases, 20
- Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 21
- Southern Medical University, Guangzhou 510080, China; 22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23	⁷ State Key Laboratory of Cardiovascular Disease and FuWai Hospital, Chinese
24	Academy of Medical Sciences and Peking Union Medical College, Beijing 100037,
25	China;
26	⁸ Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School
27	of Medicine, Tongji University, Shanghai 200433, China.
28	[#] These authors contributed equally to this work as co-first authors.
29	*These authors contributed equally to this study as co-corresponding authors.
30	Address for Correspondence:
31	Zhi-Cheng Jing, MD, PhD
32	Department of Cardiology, Guangdong Institute of Cardiovascular Diseases,
33	Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences,
34	Southern Medical University, No.106, Zhongshan 2nd Road, Guangzhou 510080,
35	China.

- 36 Tel: +86-13501353191
- 37 E-mail: jingzhicheng@vip.163.com
- 38 Wen-Hui Wu, MD
- 39 Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School
- 40 of Medicine, Tongji University, Shanghai 200433, China, No.507, Zhengmin Road,
- 41 Shanghai 200433, China.
- 42 Tel: +86-13917180587
- 43 E-mail: wenhui5621006@126.com
- 44 Chun-Yan Cheng, MD

- 45 Department of Cardiology, Guangdong Institute of Cardiovascular Diseases,
- 46 Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences,
- 47 Southern Medical University, No.106, Zhongshan 2nd Road, Guangzhou 510080,
- 48 China.
- 49 Tel: +86-20-83827812
- 50 E-mail: 073047chengchunyan@163.com
- 51 Word Count for main text: 3773

52 Abstract

53	Background: BNP (brain natriuretic peptide) or NT-proBNP (N-terminal proBNP) is
54	the only blood biomarker in the established risk calculators for pulmonary arterial
55	hypertension (PAH). New plasma biomarkers of systemic origin may improve the risk
56	assessment in PAH.
57	Methods: We utilized a robust mass spectrometry-based method to identify
58	prognostic plasma IgG N-glycome traits in PAH patients from two national referral
59	centers in China (Beijing [discovery] cohort, n = 273; Shanghai cohort [validation], n
60	= 349). Then the candidate IgG N-glycan traits were evaluated in combined cohorts
61	adjusted for potential confounders and subgroup analyses. At last, the candidate IgG
62	N-glycan traits were further evaluated against the established prognostic risk equation
63	(three-strata model from the SPAHR and COMPERA analyses) for PAH. The primary
64	endpoint was all-cause mortality.
65	Results: IgG Fucosylation was found to predict survival independent of age and sex
66	in the discovery cohort (HR: 0.377, 95% CI: 0.168-0.845, $P = 0.018$) with
67	confirmation in the validation cohort (HR: 0.264, 95% CI: 0.445-0.751, $P = 0.005$).
68	IgG Fucosylation remained a robust predictor of mortality in PAH patients in the
69	combined cohorts adjusting for potential confounders and in subgroup analyses based
70	on sex and treatment strategies. Moreover, the addition of the IgG Fucosylation to the
71	established three-strata model significantly improved the predictive accuracy from
72	AUC of 0.67 to AUC of 0.70 ($P = 0.043$) and IgG Fucosylation was useful in further
73	stratifying the intermediate risk PAH patients classified by the three-strata model into

- 74 intermediate-low and intermediate-high risk subgroups.
- 75 Conclusions: The plasma IgG Fucosylation informs prognosis independent of the
- existing clinical assessments in PAH and may be useful in the clinical management of
- 77 patients with PAH.
- 78
- 79 Keywords: IgG N-glycans, pulmonary arterial hypertension, biomarker, prognosis,
- 80 risk stratification, fucosylation

81 Non-standard Abbreviations and Acronyms

- 82 6MWD: 6-minute walking distance
- 83 AUC: area under the curve
- 84 NT-proBNP: N-terminal pro-B-type natriuretic peptide
- 85 PAH: pulmonary arterial hypertension
- 86 PVR: pulmonary vascular resistance
- 87 RAP: right arterial pressure
- 88 ROC: receiver-operating characteristic
- 89 SvO₂: mixed venous oxygen saturation
- 90 WHO FC: World Health Organization functional class

92 Clinical Perspective

93 What is new?

- The plasma IgG Fucosylation, which is in different pathophysiological pathways
- 95 from other established risk factors of pulmonary arterial hypertension (PAH), can
- 96 inform prognosis independent of the existing clinical assessments in patients with

97 PAH.

- The addition of the IgG Fucosylation to the established three-strata model for PAH
 prognosis significantly improved the predictive accuracy.
- IgG Fucosylation was useful in further stratifying the intermediate risk PAH
 patients classified by the three-strata model into intermediate-high and
 intermediate-low risk subgroups.
- 103 What are the clinical implications?
- Plasma IgG N-glycan biomarkers may provide a refined risk stratification in PAH
- used in combination with the established risk factors.
- IgG Fucosylation involved in inflammatory pathways may not only be a promising
- prognostic biomarker but also a potential novel therapeutic target, distinct fromexisting targets, for patients with PAH.

110 Introduction

111	Pulmonary arterial hypertension (PAH) represents a rare and malignant
112	cardiopulmonary condition characterized by dysregulation of endothelium-derived
113	vasoactive factors, inflammatory processes, and obstructive remodeling of small
114	pulmonary arteries. These pathological changes lead to a progressive increase in
115	pulmonary vascular resistance (PVR) and mean pulmonary artery pressure,
116	culminating in right heart failure and, ultimately, death for the majority of affected
117	patients. ^{1,2}
118	
119	The prognosis of PAH remains poor with an estimated 5-year survival rate of 60% for
120	patients with advanced PAH. ³⁻⁵ Nevertheless, treatment response varies between
121	patients due to the heterogeneity of the disease, ⁶ and life expectancy is quite variable.
122	Risk stratification and regular assessment of disease severity are vital to guide the
123	clinical management of patients with PAH. ^{1,2} The existing guidelines recommend
124	multiparametric risk calculators based on clinical assessment, right ventricular
125	function, exercise, and hemodynamic variables to inform prognosis and guide
126	treatment decision-making in PAH. ^{1,2} However, the multidimensional approach
127	suffers from some disadvantages and limitations, such as not all these measurements
128	available at each patient visit, some factors obtained invasively, unsatisfied accuracy,
129	and restricted mechanisms reflected by the parameters. Moreover, in the established
130	multifactorial prognostic model, the circulating biomarker includes only BNP (brain
131	natriuretic peptide) or NT-proBNP (N-terminal proBNP). Abnormal immune

132	regulation and inflammation have been recognized as critical contributors to the
133	pathogenesis of PAH. ⁷⁻⁹ New plasma biomarkers of systemic origin reflecting
134	different components of the pathophysiology of PAH such as immune dysregulation
135	and inflammation may improve the risk assessment of PAH and provide a more
136	sensitive measure of disease severity and therapeutic response.

137

138	Glycosylation is a prevalent and important post-translational modification that
139	modulates a variety of biological functions. ^{10,11} Abnormal glycosylation of proteins is
140	thought to play a role in almost every major disease. ^{12,13} IgG, the predominant
141	glycoprotein and antibody in human biofluids, is a key effector of the humoral
142	immune system and has multiple roles in maintaining the balance of inflammation at
143	the systemic level. ¹⁴ The conserved N-linked glycans bound to the unique
144	glycosylation site Asn297 in the Fc domain of IgG are of the complex biantennary
145	type. ^{15,16} The N-glycan compositions on IgG, particularly the core fucose moiety and
146	the terminal galactose or sialic acids, exhibit variability and hold pivotal roles in
147	regulating IgG structural stability and functional activity, which influences the
148	outcome of the immune response (e.g., antibody's effector functions). ¹⁷ For example,
149	it has been widely acknowledged that decreased levels of IgG core fucose contribute
150	to increased antibody-dependent cellular cytotoxicity (ADCC) and inflammation. ¹⁸⁻²¹
151	IgG loss of terminal galactose could trigger a proinflammatory response. ^{22,23} It is
152	noteworthy that our team has previously demonstrated dysregulation of the plasma
153	IgG N-glycome in patients with chronic thromboembolic pulmonary hypertension ²⁴

154	and the identified abnormal IgG N-glycan traits may play a crucial role in the
155	pathogenesis and progression of this condition. ²⁴ Nevertheless, the glycosylation
156	characteristics of IgG and their prognostic value in patients with PAH have not yet
157	been explored.
158	
159	The main objective of this study was to identify and validate plasma IgG N-glycan
160	traits that predict survival in patients with PAH to improve risk stratification.
161	

162 Methods

163 **Study population**

From October 2006 to December 2019, all consecutive patients with a definite 164 165 diagnosis of idiopathic PAH or heritable PAH at two national pulmonary hypertension referral centres (Shanghai Pulmonary Hospital with patients mainly from South China 166 and FuWai Hospital in Beijing with patients mainly from North China) were included 167 in this study. Idiopathic PAH was diagnosed based on baseline right heart 168 catheterization confirming newly diagnosed precapillary pulmonary hypertension, 169 defined by a resting mean pulmonary artery pressure≥25 mmHg, pulmonary artery 170 wedge pressure <15 mmHg, and PVR>3 Wood units, in the absence of other known 171 causes of PAH.^{1,2} Patients with PAH were diagnosed with heritable PAH if their first or 172 second-degree relatives had a confirmed PAH diagnosis or died from a PAH-like 173 syndrome.^{1,2} The ethics review boards of Shanghai Pulmonary Hospital and FuWai 174 Hospital approved the protocols. Written informed consent was obtained from all 175

176 patients. This study complied with the principles of the Declaration of Helsinki.

177

178 Baseline blood samples, data collection, and follow-up

Baseline demographic and clinical characteristics, including World Health 179 180 Organization functional class (WHO FC), 6-minute walking distance (6MWD), and invasive haemodynamics including right arterial pressure (RAP), mean pulmonary 181 artery pressure, pulmonary artery wedge pressure, cardiac index, PVR, and mixed 182 venous oxygen saturation (SvO₂) were collected. Baseline venous plasma for IgG N-183 184 glycome profiling and haemodynamic data were obtained during the first diagnostic right heart catheterization. Follow-ups were carried out through clinic visits or phone 185 or internet interviews, and the patient's survival time was calculated by months from 186 187 the initial PAH diagnosis date to January 2023 or the latest contact date. The primary clinical endpoint was all-cause mortality. 188

189

190 Mass spectrometric IgG N-glycome profiling

191 The profiling of IgG N-glycome was carried out using matrix-assisted laser

desorption/ionization time-of-flight mass spectrometry,²⁵⁻²⁷ with raw mass

- 193 spectrometry data processing performed according to established methods outlined in
- 194 previous reports.²⁵⁻²⁷ Detailed procedures are provided in the Supplementary Material

195 for reference.

196

197 To combine the effects of individual detected N-glycan traits sharing similar

198	structures and better interpret the biological effects of IgG N-glycosylation, ^{28,29}
199	derived (calculated) N-glycan traits representing the most important features of IgG
200	N-glycosylation including Galactosylation, Bisecting N-acetylglucosamine, and
201	Fucosylation were calculated from the directly detected N-glycans. The formulas used
202	for the calculation: Galactosylation = H3N4F1/(H4N4F1 + 2*H5N4F1); Bisecting N-
203	acetylglucosamine = H3N5F1 + H4N5F1 + H5N5F1; Fucosylation = H3N4F1 +
204	H4N4F1 + H3N5F1 + H5N4F1 + H4N5F1 + H5N5F1 (H = hexose; N = N-
205	acetylhexosamine; $F = deoxyhexose [fucose]$). ^{24,27} GlycoWorkbench software
206	(version 1.1.3480) was used to annotate the N-glycan structures.
207	
208	Statistical analysis
209	Normality was determined using the Kolmogorov-Smirnov test. Continuous variables
210	were presented as mean \pm SD for normally distributed data, and as median
211	(interquartile range, 25% to 75%) for non-normally distributed variables. Categorical
212	variables were presented as n (%). Statistical analysis was performed with Statistic
213	Package for Social Science (SPSS Inc., Chicago, USA) version 22.0 and GraphPad
214	Prism version 8.0.0 for Windows (GraphPad Software, San Diego, California USA,
215	www.graphpad.com). All tests were two-tailed with a value of P<0.05 considered
216	statistically significant.
217	
218	Prognostic IgG N-glycan traits were identified by Cox regression analysis corrected

219 for age and sex in the discovery cohort and confirmed in the validation cohort. To

220	assess whether the prognostic IgG N-glycan trait screened out was an independent
221	prognostic factor, Cox regression analysis adjusted for potential confounders
222	including age, sex, type of PAH, treatment strategies, 6MWD, WHO FC, NT-proBNP,
223	RAP, SvO ₂ , and cardiac index were conducted. Further adjusted Cox regression
224	analyses were conducted in subgroups stratified by sex and therapeutic strategies. To
225	assess the added value of IgG N-glycan traits to the established risk model, we
226	compared the prognostic accuracy of the three-strata model (the established
227	prognostic risk equation derived from the SPAHR and the COMPERA registry) ^{30,31}
228	with that of the IgG N-glycan + three-strata model using receiver-operating
229	characteristic (ROC) analysis. Additionally, IgG N-glycans were employed to further
230	stratify PAH patients classified as intermediate risk by the three-strata model, utilizing
231	Kaplan-Meier survival analysis. The optimal cut-off values for the prognostic IgG N-
232	glycan traits in Kaplan-Meier and Cox regression analyses were determined based on
233	the values that maximized the sum of sensitivity and specificity in ROC analysis. ³²
234	
235	Results

236 Study population and baseline characteristics

237 The study design is illustrated in Figure 1. A total of 273 patients with PAH enrolled

from Fuwai Hospital between 2013 and 2019 (discovery cohort) and 349 patients with

239 PAH enrolled from Shanghai Pulmonary Hospital between 2006 and 2013 (validation

cohort) were included in this study.

241

242	Among the patients, 58 (21.2%) in the discovery cohort and 109 (31.2%) in the
243	validation cohort were male. The mean ages were 32.8 ± 10.4 and 35.9 ± 16.8 years in
244	the discovery and validation cohorts, respectively. In the discovery cohort, 11 (4.0%)
245	patients received untargeted therapy, 80 (29.3%) patients received monotherapy, 148
246	(54.2%) patients received dual therapy, and 34 (12.5%) patients received triple
247	therapy. In the validation cohort, 66 (18.9%) patients received untargeted therapy, 227
248	(65.0%) patients received monotherapy, 53 (15.2%) patients received dual therapy,
249	and 3 (0.9%) patients received triple therapy (Table 1).
250	
251	Follow-up
252	During a median follow-up of 39 (22-63) months, 41 patients (6.6%, 2 in the
253	discovery cohort and 39 in the validation cohort) were lost to follow-up. In total, 139
254	patients (n = 52 in the discovery cohort and n = 87 in the validation cohort) died at the
255	end of the follow-up periods.
256	
257	Plasma IgG N-glycome profiles in patients with PAH
258	Eight IgG N-glycans were directly detected in our cohorts by matrix-assisted laser
259	desorption/ionization time of flight mass spectrometry. The representative annotated
260	mass spectrometry spectra of the IgG N-glycome profiles from the survivor and non-
261	survivor in our PAH cohorts are provided in Supplemental Figure S1, which
262	demonstrates variations in peak patterns between the two groups. As derived N-glycan

263 traits represent glycosylation changes shared by a group of structurally related N-

264	glycans and enable better interpretation of the biological effects of glycosylation than
265	directly detected N-glycan traits, three derived N-glycan traits including
266	Galactosylation, Bisecting N-acetylglucosamine, and Fucosylation were calculated
267	from the eight directly detected IgG N-glycans. We mainly evaluated IgG derived N-
268	glycan traits in the present study.
269	
270	Identification of prognostic IgG N-glycan traits in patients with PAH
271	Discovery and validation cohorts were used to evaluate the associations of IgG N-
272	glycan traits with the survival of patients. In the discovery cohort, Galactosylation
273	(HR: 2.257, 95% CI: 1.274–4.001, <i>P</i> = 0.005; Figure 2A) and Fucosylation (HR:
274	0.377, 95% CI: 0.168–0.845, $P = 0.018$; Figure 2A) were found to predict survival
275	independent of age and sex. Bisecting N-acetylglucosamine had no prognostic value
276	(HR: 0.617, 95% CI: 0.219-1.737, <i>P</i> = 0.361; Figure 2A). We continued to validate
277	our results in the validation cohort. However, only Fucosylation was confirmed to be
278	associated with all-cause death independent of age and sex (HR: 0.264, 95% CI:
279	0.445–0.751, $P = 0.005$; Figure 2B) and the prognostic effect of Galactosylation was
280	not replicated (HR: 1.092, 95% CI: 0.694–1.717, <i>P</i> = 0.705; Figure 2B). The
281	Bisecting N-acetylglucosamine remained of no prognostic value in the validation
282	cohort (HR: 1.789, 95% CI: 0.554–5.776, <i>P</i> = 0.330; Figure 2B). Finally, IgG
283	Fucosylation was identified as a promising candidate prognostic glycan biomarker,
284	which was further validated below.

286 The validation of the prognostic value of IgG Fucosylation

287	We further evaluated the prognostic significance of IgG Fucosylation in the combined
288	cohorts. In total, death occurred in 13.1% (25 out of 191) and 29.2% (114 out of 390)
289	of patients in the high and low IgG Fucosylation groups, respectively, resulting in
290	respective 5-year survival rates of 88.5% and 74.6% ($P < 0.001$ for the log-rank test;
291	Figure 3).

292

293	To evaluate	whether IgG F	Fucosylation	independently	impacts t	he outcome of	patients
-----	-------------	---------------	--------------	---------------	-----------	---------------	----------

with PAH, Cox regression models were further adjusted for potential confounders

including 6MWD, WHO FC, NT-proBNP, RAP, SvO₂, cardiac index, type of PAH,

and treatment strategies in addition to age and sex. Our results showed that the low

297 IgG Fucosylation was still significantly associated with a high risk of all-cause death

in patients with PAH (HR: 0.490; 95% CI: 0.315–0.763; *P* = 0.002; Table 2; Figure 4).

299

300 Furthermore, in order to comprehensively demonstrate the prognostic value of IgG

301 Fucosylation, we further conducted subgroup analyses based on sex and therapeutic

302 strategies. Our results showed that even after stratifying by sex, the association

303 between low IgG Fucosylation and increased all-cause mortality remained robust and

304 there was no significant interaction between sex and IgG Fucosylation (P=0.784;

Table 2); Interestingly, low Fucosylation posed a greater risk for males (fully adjusted

306 models; male: HR: 0.387, 95% CI: 0.159-0.941, P = 0.035 and female: HR: 0.527,

307 95% CI: 0.307–0.906, P = 0.014; Table 2; Figure 4). Furthermore, we did not observe

308	interactions between IgG Fucosylation and the rapeutic strategies (P = 0.410; Table 2).
309	We found that IgG Fucosylation continued to independently predict survival within
310	subgroups stratified based on therapeutic strategies (fully adjusted models; dual and
311	triple therapy: HR: 0.376, 95% CI: 0.148–0.954, $P = 0.043$; treatment naïve and
312	monotherapy: HR: 0.595, 95% CI: 0.354–1, <i>P</i> = 0.033; Table 2; Figure 4).
313	
314	At last, we investigated whether the IgG Fucosylation offered improvements in risk
315	prediction in addition to the established prognostic risk equation (three-strata model
316	from the SPAHR and COMPERA analyses) ^{30,31} in PAH. We found the addition of IgG
317	Fucosylation to the three-strata model improved the prediction of outcomes from area
318	under the curve (AUC) 0.67 (95%CI: 0.62–0.72) to 0.70 (95%CI: 0.65–0.75) by ROC
319	analysis ($P = 0.043$ for the difference in AUC) (Figure 5). In addition, about 60% of
320	patients in our cohort met intermediate risk criteria in the tree-strata model (Figure
321	6A) which was consistent with previous reports, and IgG Fucosylation was useful in
322	further dividing patients in the intermediate risk group into intermediate-high and
323	intermediate-low risk subgroups ($P < 0.001$, Figure 6B).

324

325 **Discussion**

326 Risk stratification has become an essential part of the management of patients with

327 PAH. The joint guidelines on pulmonary hypertension released in 2015 by the

328 European Society of Cardiology (ESC) and the European Respiratory Society (ERS)

329 introduced a multidimensional risk stratification model integrating 14 variables

330	obtained from nine distinct assessments. According to this model, the risk is
331	categorized into three strata: low, intermediate, or high. ^{1,2} However, based on the
332	three-strata model, the majority of patients with PAH were classified as intermediate
333	risk. ^{30,31} Despite the development of refined or alternative methods, such as the
334	prognostic risk equation from the French, ³³ SPAHR, ³⁴ REVEAL, ³⁵ and COMPERA ³⁶
335	Registries, challenges persist regarding the accuracy of stratification and the
336	consistent availability of various clinical parameters during every patient visit. These
337	limitations underscore the need for improvement in the approach to assessing the risk
338	of PAH. In this context, several researchers have attempted to develop new protein
339	biomarkers/panels from blood samples to improve risk assessment. ³⁷⁻³⁹ Although
340	these studies have made significant contributions to exploring novel biomarkers for
341	PAH, the latest 2022 ESC/ERS guidelines for PAH continued to recommend NT-
342	proBNP as the exclusive blood biomarker. ⁴⁰ Significantly, the studies of glycosylation
343	of plasma proteins as potential biomarkers also shed new light on this field. The roles
344	of plasma IgG N-glycosylation in cardiovascular diseases have been long investigated
345	and discussed. The IgG glycosylation profile was found to be associated with
346	cardiovascular disease risk score and subclinical atherosclerosis.41 Additionally,
347	alteration in plasma IgG N-glycosylation profiles was reported to be associated with
348	blood pressure status, suggesting that IgG N-glycans may be potential postgenomic
349	biomarkers for hypertension. ⁴² Notably, our recent discovery showcased the utility of
350	IgG Gal-ratio, representing the distribution of IgG galactosylation, in evaluating the
351	inflammatory state in patients with chronic thromboembolic pulmonary

hypertension.²⁴ These investigations underscored the immense promise of IgG Nglycans as biomarkers for the identification and prognostication of cardiovascular
diseases. However, whether IgG N-glycans can be used as prognostic biomarkers for
PAH remains to be explored.

356

To our knowledge, this is the first IgG N-glycomic study in PAH. Applying a robust 357 method based on high-throughput mass spectrometry, we for the first time identified 358 and validated that plasma IgG Fucosylation informs patients' survival independent of 359 360 established risk factors. We first screened out the promising candidate prognostic marker IgG Fucosylation in the discovery cohort and validated it in another 361 independent cohort. We then demonstrated that low plasma IgG Fucosylation was 362 363 robustly associated with an increased risk of death in patients with PAH not only through overall analysis adjusted for potential confounders but also through subgroup 364 analyses. At last, we found that the prognostic IgG Fucosylation improved the clinical 365 366 risk prediction of the established prognostic risk equation (three-strata model from the SPAHR and COMPERA analyses).^{30,31} This study adopted a rigorous validation 367 scheme as used in other biomarker discovery studies, encompassing the stages of 368 discovery (Beijing cohort), validation (Shanghai cohort), and random sampling 369 analysis (combined cohorts). This comprehensive approach provided robust evidence 370 supporting IgG Fucosylation as a significant prognostic factor in PAH, instilling 371 confidence in the reliability of our findings. 372

373

374	Registries worldwide have consistently indicated a higher prevalence but better
375	prognosis among female patients with PAH. ⁴³ Interestingly, in the present study, we
376	also observed sex-related differences and low IgG Fucosylation appeared to pose a
377	higher risk in men compared to that in women. Furthermore, in our subgroup analysis
378	based on therapeutic strategies, our results demonstrated that baseline IgG
379	Fucosylation effectively distinguished low-risk and high-risk patients, not only within
380	the treatment-naïve and monotherapy subgroup but also within the dual and triple
381	therapy subgroup. Despite the substantial advancements in the modern era of PAH
382	treatment, a specific subset of patients continues to face a bleak prognosis.
383	Remarkably, baseline IgG Fucosylation could still discern this subset of patients with
384	adverse outcomes in the context of dual and triple therapy. However, the previously
385	established three-strata model was less effective in predicting outcomes in modern
386	treatment settings compared to monotherapy or treatment-naive subgroups (data not
387	shown). One potential explanation is that the current treatments do not target
388	inflammatory pathways associated with IgG Fucosylation. Although modern dual and
389	triple therapies significantly improve patient survival compared to monotherapy or
390	treatment naïve, this improvement is unrelated to systemic-originated IgG
391	Fucosylation. Baseline IgG Fucosylation can still sensitively predict survival, even
392	more so in the dual and triple therapy groups. These findings suggested IgG
393	Fucosylation may not only be a promising prognostic biomarker but also emerge as a
394	potential novel therapeutic target, distinct from existing targets, for patients with PAH.
395	

396	In the SPAHR and COMPERA analyses, the majority of patients with PAH were
397	identified as intermediate risk (~60-70%) ^{$30,31$} and similar results were also obtained in
398	our cohorts using the three-strata model they proposed. Identifying high-risk patients
399	is particularly important in the risk assessment at diagnosis. ^{44,45} Discriminating the
400	intermediate-high risk group from the intermediate risk group that makes up the
401	majority of the patients may prompt physicians to initiate more aggressive initial
402	treatment strategies which have far-reaching effects on patients' long-term survival.44
403	Therefore, a more granular risk stratification is needed for the patients in the
404	intermediate risk group, which is vitally important for therapeutic decisions. Several
405	reports have shown that the use of additional variables improved risk prediction and
406	some groups also proposed the four-strata risk model. ^{36,46-48} In the present study, the
407	potential plasma biomarker IgG Fucosylation also achieved promising results with
408	further discrimination within the intermediate risk group. Specifically, the IgG
409	Fucosylation improved discrimination AUC from 0.67 (uninformative test) to 0.70
410	(moderately accurate test) and reclassification of patients in the intermediate risk
411	group into intermediate-high and intermediate-low risk of the three-strata model,
412	suggesting IgG Fucosylation provided added values in the risk stratification of PAH in
413	combination with the established clinical targets.
414	

Several studies have shown that core fucose on IgG plays a role in the progression of
malignant diseases.^{49,50} Functional studies revealed that the lack of core fucose in IgG
N-glycome greatly increased the proinflammatory capacity of IgG through increased

418	binding of IgG to FcyRIII and enhanced ADCC. ^{51,52} Decreased levels of core
419	Fucosylation of IgG N-glycome coincide with increased inflammation in
420	individuals. ²⁰ Moreover, in our previous study, we found human plasma IgG N-
421	glycome profiles exhibited a proinflammatory phenotype in chronic thromboembolic
422	pulmonary hypertension and IgG proinflammatory N-glycans may be useful for
423	assessing the occurrence and prognosis of patients with chronic thromboembolic
424	pulmonary hypertension. ²⁴ In the present study, decreased levels of IgG Fucosylation
425	were found associated with increased mortality of patients with PAH. Therefore, we
426	speculate that inflammation could be a mediator of the prognostic effect of IgG
427	Fucosylation in patients with PAH, but the potential role of changes in IgG
428	Fucosylation in the development and progression of PAH deserves in-depth
429	exploration in future studies.
429 430	exploration in future studies.
429 430 431	exploration in future studies. Circulating BNP or NT-proBNP secreted by cardiac myocytes in response to
429 430 431 432	exploration in future studies. Circulating BNP or NT-proBNP secreted by cardiac myocytes in response to increased ventricle wall strain ⁵³ is the only blood biomarker in the established risk
 429 430 431 432 433 	exploration in future studies. Circulating BNP or NT-proBNP secreted by cardiac myocytes in response to increased ventricle wall strain ⁵³ is the only blood biomarker in the established risk calculators. Besides cardiac-originated BNP or NT-proBNP, systemic-originated IgG
 429 430 431 432 433 434 	exploration in future studies. Circulating BNP or NT-proBNP secreted by cardiac myocytes in response to increased ventricle wall strain ⁵³ is the only blood biomarker in the established risk calculators. Besides cardiac-originated BNP or NT-proBNP, systemic-originated IgG Fucosylation which is associated with systemic immune and inflammation was found
 429 430 431 432 433 434 435 	exploration in future studies. Circulating BNP or NT-proBNP secreted by cardiac myocytes in response to increased ventricle wall strain ⁵³ is the only blood biomarker in the established risk calculators. Besides cardiac-originated BNP or NT-proBNP, systemic-originated IgG Fucosylation which is associated with systemic immune and inflammation was found to provide independent values to inform risk stratification in this study. Therefore,
 429 430 431 432 433 434 435 436 	exploration in future studies. Circulating BNP or NT-proBNP secreted by cardiac myocytes in response to increased ventricle wall strain ⁵³ is the only blood biomarker in the established risk calculators. Besides cardiac-originated BNP or NT-proBNP, systemic-originated IgG Fucosylation which is associated with systemic immune and inflammation was found to provide independent values to inform risk stratification in this study. Therefore, plasma biomarkers from different pathways in the pathophysiology of PAH
 429 430 431 432 433 434 435 436 437 	exploration in future studies. Circulating BNP or NT-proBNP secreted by cardiac myocytes in response to increased ventricle wall strain ⁵³ is the only blood biomarker in the established risk calculators. Besides cardiac-originated BNP or NT-proBNP, systemic-originated IgG Fucosylation which is associated with systemic immune and inflammation was found to provide independent values to inform risk stratification in this study. Therefore, plasma biomarkers from different pathways in the pathophysiology of PAH collectively provide more comprehensive information compared to parameters
 429 430 431 432 433 434 435 436 437 438 	exploration in future studies. Circulating BNP or NT-proBNP secreted by cardiac myocytes in response to increased ventricle wall strain ⁵³ is the only blood biomarker in the established risk calculators. Besides cardiac-originated BNP or NT-proBNP, systemic-originated IgG Fucosylation which is associated with systemic immune and inflammation was found to provide independent values to inform risk stratification in this study. Therefore, plasma biomarkers from different pathways in the pathophysiology of PAH collectively provide more comprehensive information compared to parameters indicating limited mechanisms. On the other hand, though previous studies have

440	stratification of PAH, IgG Fucosylation identified in the present study is the first
441	glycomic candidate biomarker for PAH prognosis. Glycomic biomarkers have many
442	advantages over other omic markers. Especially, clinical IgG N-glycosylation analysis
443	does not rely as heavily on mild serum/plasma storage conditions and timely analysis
444	(glycans are even stable at 50 $^{\circ}$ C for two weeks) as many other omics analyses. ⁵⁴ It is
445	worth mentioning that the high-throughput workflow for IgG N-glycome profiling
446	applied in the present study has been widely used in various studies, ^{24-27,55} enabling
447	the candidate glycan biomarker to be more convenient for further clinical application.
448	
449	Strengths and limitations
450	A major advantage of this study is that we, for the first time, reliably identified and
451	validated a novel independent prognostic biomarker plasma IgG Fucosylation for
452	PAH using plasma IgG N-glycomics based on relatively large and independent
453	multicenter PAH cohorts with long-term follow-up. Another strength of our study was
454	that the IgG glycan biomarker is systemic-originated and in different pathways of the
455	pathophysiology of PAH from other established risk factors, which provided added
456	values for the prognostication of patients with PAH. Nonetheless, our study has
457	several limitations. First, only idiopathic and heritable PAH were included in our
458	cohorts. The survival in patients with other types of PAH (caused by other associated
459	conditions such as congenital heart disease, connective tissue diseases, and
100	
460	portopulmonary hypertension) may differ significantly from that of patients with

462	study to other categories of PAH requires extreme caution and the prognostic
463	significance of IgG Fucosylation in other subtypes of PAH will be evaluated in future
464	studies. Second, in the present study, we discovered that decreased levels of IgG
465	Fucosylation were independently associated with an increased risk of death in patients
466	with PAH. Though some functional studies have shown that the absence of core
467	fucose in IgG N-glycome affects inflammatory signaling and immune response
468	outcomes, the mechanisms underlying our findings and the potential role of altered
469	IgG Fucosylation in the development and progression of PAH warrant in-depth
470	investigation. Third, we evaluated the prognostic value of baseline plasma IgG N-
471	glycome profiles in PAH. Future investigations should explore the clinical
472	implications of IgG N-glycome variations in patients undergoing diverse stages of
473	treatment. Last, though the sample size of our cohorts was relatively large, the
474	numbers became small in the subgroups of sensitivity analyses and stratified analyses.
475	The accuracy of IgG Fucosylation in prognostication would be increased with an
476	increased number of samples.
477	

478 Conclusions

- 479 Through a comprehensive scheme, we identified and validated a plasma glycomic
- 480 prognostic biomarker, which is in different pathophysiological pathways from other
- 481 established risk factors of PAH, to risk stratify patients with PAH.

482

483 Acknowledgements

484 Aution Contributions	484	Author Contributions
--------------------------	-----	----------------------

- 485 Conception and design: ZCJ, ZJZ, CL, WHW, JLM, and CYC; Analysis and
- 486 interpretation of data: ZJZ, CL, JLM, YPZ, DL, TYL, JHL, SJZ, JSM, RNL, and LW;
- 487 Drafting of the manuscript: ZJZ and CL; Critical revision of the manuscript for
- 488 important intellectual content: ZCJ, JLM, DL, and YPZ; Final approval of the
- 489 manuscript: all authors; Statistical expertise: KS; Obtaining research funding: ZCJ
- 490 and ZJZ; Acquisition of data: LC, ZJZ, JHL, WHW, CYC, and DL.
- 491

492 Sources of funding

- 493 This work was supported by grants from the National Key Research and Development
- 494 Program of China (2022YFC2703902 and 2022YFC2703901), the CAMS Innovation
- 495 Fund for Medical Sciences (2021-I2M-1-018), National Natural Science Foundation
- 496 of China (82241020 and 32371506), Natural Science Foundation of Shanghai
- 497 (22ZR1452400), Pujiang Talent Program (22PJD064), and National High-Level
- 498 Hospital Clinical Research Funding (2022-PUMCH-B-099 and 2022-PUMCH-A-

499 200).

- 500
- 501 Disclosures

502 None

503

504 Supplemental materials

505 Supplemental methods

506 Supplemental Figure S1

507

508 References

509	1.	Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G,
510		Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines
511		for the diagnosis and treatment of pulmonary hypertension: The Joint Task
512		Force for the Diagnosis and Treatment of Pulmonary Hypertension of the
513		European Society of Cardiology (ESC) and the European Respiratory Society
514		(ERS): Endorsed by: Association for European Paediatric and Congenital
515		Cardiology (AEPC), International Society for Heart and Lung Transplantation
516		(ISHLT). Eur Heart J. 2016;37:67-119. doi: 10.1093/eurheartj/ehv317
517	2.	Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G,
518		Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines
519		for the diagnosis and treatment of pulmonary hypertension: The Joint Task
520		Force for the Diagnosis and Treatment of Pulmonary Hypertension of the
521		European Society of Cardiology (ESC) and the European Respiratory Society
522		(ERS): Endorsed by: Association for European Paediatric and Congenital
523		Cardiology (AEPC), International Society for Heart and Lung Transplantation
524		(ISHLT). Eur Respir J. 2015;46:903-975. doi: 10.1183/13993003.01032-2015
525	3.	Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A,
526		Weitzenblum E, Cordier JF, Chabot F, et al. Survival in patients with
527		idiopathic, familial, and anorexigen-associated pulmonary arterial

500		
528		hypertension in the modern management era. Circulation. 2010;122:156-163.
529		doi: 10.1161/CIRCULATIONAHA.109.911818
530	4.	Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E,
531		Romero AJ, Benton WW, Elliott CG, McGoon MD, et al. Five-Year outcomes
532		of patients enrolled in the REVEAL Registry. Chest. 2015;148:1043-1054.
533		doi: 10.1378/chest.15-0300
534	5.	Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An
535		evaluation of long-term survival from time of diagnosis in pulmonary arterial
536		hypertension from the REVEAL Registry. Chest. 2012;142:448-456. doi:
537		10.1378/chest.11-1460
538	6.	Pan HM, McClelland RL, Moutchia J, Appleby DH, Fritz JS, Holmes JH,
539		Minhas J, Palevsky HI, Urbanowicz RJ, Kawut SM, et al. Heterogeneity of
540		treatment effects by risk in pulmonary arterial hypertension. Eur Respir J.
541		2023;62. doi: 10.1183/13993003.00190-2023
542	7.	Evans CE, Cober ND, Dai Z, Stewart DJ, Zhao YY. Endothelial cells in the
543		pathogenesis of pulmonary arterial hypertension. Eur Respir J. 2021;58. doi:
544		10.1183/13993003.03957-2020
545	8.	Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial
546		hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492.
547		doi: 10.1136/bmj.j5492
548	9.	Ferrian SP, Cao A, McCaffrey EF, Saito T, Greenwald NF, Nicolls MR, Bruce
549		T, Zamanian RT, Del Rosario P, Rabinovitch M, et al. Single-Cell Imaging

550		Maps Inflammatory Cell Subsets to Pulmonary Arterial Hypertension
551		Vasculopathy. Am J Respir Crit Care Med. 2023. doi: 10.1164/rccm.202209-
552		1761OC
553	10.	Hart GW, Copeland RJ. Glycomics hits the big time. Cell. 2010;143:672-676.
554		doi: 10.1016/j.cell.2010.11.008
555	11.	Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and
556		disease. Cell. 2006;126:855-867. doi: 10.1016/j.cell.2006.08.019
557	12.	Memarian E, Heijmans R, Slieker RC, Sierra A, Gornik O, Beulens JWJ,
558		Hanic M, Elders P, Pascual J, Sijbrands E, et al. IgG N-glycans are associated
559		with prevalent and incident complications of type 2 diabetes. Diabetes Metab
560		Res Rev. 2023;39:e3685. doi: 10.1002/dmrr.3685
561	13.	Varki A. Biological roles of oligosaccharides: all of the theories are correct.
562		Glycobiology. 1993;3:97-130. doi: 10.1093/glycob/3.2.97
563	14.	Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG
564		modulate the immune system? Nat Rev Immunol. 2013;13:176-189. doi:
565		10.1038/nri3401
566	15.	Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of
567		glycosylation on the biological function and structure of human
568		immunoglobulins. Annu Rev Immunol. 2007;25:21-50. doi:
569		10.1146/annurev.immunol.25.022106.141702
570	16.	Simurina M, de Haan N, Vuckovic F, Kennedy NA, Stambuk J, Falck D,
571		Trbojevic-Akmacic I, Clerc F, Razdorov G, Khon A, et al. Glycosylation of

- 572 Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel
- 573 Diseases. *Gastroenterology*. 2018;154:1320-1333 e1310. doi:
- 574 10.1053/j.gastro.2018.01.002
- 575 17. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics.
- 576 *Nat Rev Drug Discov.* 2009;8:226-234. doi: 10.1038/nrd2804
- 577 18. Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, Gornik
- 578 O, Supraha-Goreta S, Wormald MR, Redzic I, et al. High throughput isolation
- and glycosylation analysis of IgG-variability and heritability of the IgG
- 580 glycome in three isolated human populations. *Mol Cell Proteomics*.
- 581 2011;10:M111 010090. doi: 10.1074/mcp.M111.010090
- Scanlan CN, Burton DR, Dwek RA. Making autoantibodies safe. *Proc Natl Acad Sci U S A*. 2008;105:4081-4082. doi: 10.1073/pnas.0801192105
- 584 20. Freidin MB, Keser T, Gudelj I, Stambuk J, Vucenovic D, Allegri M, Pavic T,

Pain and Composition of IgG Glycome. Sci Rep. 2016;6:26815. doi:

Simurina M, Fabiane SM, Lauc G, et al. The Association Between Low Back

- 587 10.1038/srep26815

585

- 588 21. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. Expression of
- 589 GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of
- antibodies with altered glycoforms leads to an increase in ADCC through
- 591 higher affinity for FC gamma RIII. *Biotechnol Bioeng*. 2001;74:288-294.
- 592 22. Mihai S, Nimmerjahn F. The role of Fc receptors and complement in
- 593 autoimmunity. *Autoimmun Rev.* 2013;12:657-660. doi:

594		10.1016/j.autrev.2012.10.008
595	23.	Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M,
596		McDonald JU, Orr SJ, Berger M, Petzold D, et al. Anti-inflammatory activity
597		of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and
598		dectin-1. Nat Med. 2012;18:1401-1406. doi: 10.1038/nm.2862
599	24.	Zhang ZJ, Wang HF, Lian TY, Zhou YP, Xu XQ, Guo F, Wei YP, Li JY, Sun K,
600		Liu C, et al. Human Plasma IgG N-Glycome Profiles Reveal a
601		Proinflammatory Phenotype in Chronic Thromboembolic Pulmonary
602		Hypertension. Hypertension. 2023;80:1929-1939. doi:
603		10.1161/HYPERTENSIONAHA.123.21408
604	25.	Ren S, Zhang Z, Xu C, Guo L, Lu R, Sun Y, Guo J, Qin R, Qin W, Gu J.
605		Distribution of IgG galactosylation as a promising biomarker for cancer
606		screening in multiple cancer types. Cell Res. 2016;26:963-966. doi:
607		10.1038/cr.2016.83
608	26.	Qian Y, Wang Y, Zhang X, Zhou L, Zhang Z, Xu J, Ruan Y, Ren S, Xu C, Gu
609		J. Quantitative analysis of serum IgG galactosylation assists differential
610		diagnosis of ovarian cancer. J Proteome Res. 2013;12:4046-4055. doi:
611		10.1021/pr4003992
612	27.	Zhang Z, Wu J, Liu P, Kang L, Xu X. Diagnostic Potential of Plasma IgG N-
613		glycans in Discriminating Thyroid Cancer from Benign Thyroid Nodules and
614		Healthy Controls. Front Oncol. 2021;11:658223. doi:
615		10.3389/fonc.2021.658223

616	28.	Reiding KR, Blank D, Kuijper DM, Deelder AM, Wuhrer M. High-throughput
617		profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-
618		specific sialic acid esterification. Anal Chem. 2014;86:5784-5793. doi:
619		10.1021/ac500335t
620	29.	Clerc F, Reiding KR, Jansen BC, Kammeijer GS, Bondt A, Wuhrer M. Human
621		plasma protein N-glycosylation. Glycoconj J. 2016;33:309-343. doi:
622		10.1007/s10719-015-9626-2
623	30.	Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg
624		S, Wikstrom G, Radegran G. A comprehensive risk stratification at early
625		follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart
626		J. 2018;39:4175-4181. doi: 10.1093/eurheartj/ehx257
627	31.	Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N,
628		Olsson KM, Meyer K, Vizza CD, Vonk-Noordegraaf A, et al. Mortality in
629		pulmonary arterial hypertension: prediction by the 2015 European pulmonary
630		hypertension guidelines risk stratification model. Eur Respir J. 2017;50. doi:
631		10.1183/13993003.00740-2017
632	32.	Perkins NJ, Schisterman EF. The Youden Index and the optimal cut-point
633		corrected for measurement error. Biom J. 2005;47:428-441. doi:
634		10.1002/bimj.200410133
635	33.	Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, Picard F, de
636		Groote P, Jevnikar M, Bergot E, et al. Risk assessment, prognosis and
637		guideline implementation in pulmonary arterial hypertension. Eur Respir J.

- 639 34. Kylhammar D, Hjalmarsson C, Hesselstrand R, Jansson K, Kavianipour M,
- 640 Kjellstrom B, Nisell M, Soderberg S, Radegran G. Predicting mortality during
- 641 long-term follow-up in pulmonary arterial hypertension. *ERJ Open Res.*
- 642 2021;7. doi: 10.1183/23120541.00837-2020
- 643 35. Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, Elliott CG,
- 644 Farber HW. Development and Validation of an Abridged Version of the
- 645 REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With
- 646 Pulmonary Arterial Hypertension. *Chest.* 2021;159:337-346. doi:
- 647 10.1016/j.chest.2020.08.2069
- 648 36. Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grunig E, Staehler
- 649 G, Vizza CD, Gall H, Distler O, et al. COMPERA 2.0: a refined four-stratum
- 650 risk assessment model for pulmonary arterial hypertension. *Eur Respir J.*
- 651 2022;60. doi: 10.1183/13993003.02311-2021
- 652 37. Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, Gibbs
- JSR, Condliffe R, Elliot CA, Kiely DG, et al. Plasma proteome analysis in

654 patients with pulmonary arterial hypertension: an observational cohort study.

655 *Lancet Respir Med.* 2017;5:717-726. doi: 10.1016/S2213-2600(17)30161-3

- 656 38. Rhodes CJ, Wharton J, Swietlik EM, Harbaum L, Girerd B, Coghlan JG,
- 657 Lordan J, Church C, Pepke-Zaba J, Toshner M, et al. Using the Plasma
- 658 Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.
- 659 Am J Respir Crit Care Med. 2022;205:1102-1111. doi: 10.1164/rccm.202105-

660	1118OC

661	39.	Amsallem M, Sweatt AJ, Arthur Ataam J, Guihaire J, Lecerf F, Lambert M,
662		Ghigna MR, Ali MK, Mao Y, Fadel E, et al. Targeted proteomics of right heart
663		adaptation to pulmonary arterial hypertension. Eur Respir J. 2021;57. doi:
664		10.1183/13993003.02428-2020
665	40.	Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M,
666		Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, et al. 2022 ESC/ERS
667		Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur
668		Heart J. 2022;43:3618-3731. doi: 10.1093/eurheartj/ehac237
669	41.	Menni C, Gudelj I, Macdonald-Dunlop E, Mangino M, Zierer J, Besic E, Joshi
670		PK, Trbojevic-Akmacic I, Chowienczyk PJ, Spector TD, et al. Glycosylation
671		Profile of Immunoglobulin G Is Cross-Sectionally Associated With
672		Cardiovascular Disease Risk Score and Subclinical Atherosclerosis in Two
673		Independent Cohorts. Circ Res. 2018;122:1555-1564. doi:
674		10.1161/CIRCRESAHA.117.312174
675	42.	Gao Q, Dolikun M, Stambuk J, Wang H, Zhao F, Yiliham N, Wang Y,
676		Trbojevic-Akmacic I, Zhang J, Fang H, et al. Immunoglobulin G N-Glycans as
677		Potential Postgenomic Biomarkers for Hypertension in the Kazakh Population.
678		OMICS. 2017;21:380-389. doi: 10.1089/omi.2017.0044
679	43.	Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, Chaumais MC,
680		Jais X, Bertoletti L, Sitbon O, Weatherald J, et al. Sex and gender in
681		pulmonary arterial hypertension. Eur Respir Rev. 2021;30. doi:

682 10.1183/16000617.0330-2020

bout in Doubly 11, but ale D, build 11, Deigot D, Deitoletti D, Deutinei 1	683	44.	Boucly A	, Savale L	, Jais X	Bauer F.	Bergot E	, Bertoletti L	, Beurnier A
--	-----	-----	----------	------------	----------	----------	----------	----------------	--------------

- Bourdin A, Bouvaist H, Bulifon S, et al. Association between Initial Treatment
- 685 Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. Am J
- 686 *Respir Crit Care Med.* 2021;204:842-854. doi: 10.1164/rccm.202009-3698OC
- 687 45. Galie N, Channick RN, Frantz RP, Grunig E, Jing ZC, Moiseeva O, Preston
- 688 IR, Pulido T, Safdar Z, Tamura Y, et al. Risk stratification and medical therapy
- of pulmonary arterial hypertension. *Eur Respir J.* 2019;53. doi:
- 690 10.1183/13993003.01889-2018
- 691 46. Harbaum L, Fuge J, Kamp JC, Hennigs JK, Simon M, Sinning C, Oqueka T,
- 692 Grimminger J, Olsson KM, Hoeper MM, et al. Blood carbon dioxide tension
- and risk in pulmonary arterial hypertension. *Int J Cardiol*. 2020;318:131-137.
- 694 doi: 10.1016/j.ijcard.2020.06.069
- 695 47. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, Jais X,
- Taniguchi Y, O'Connell C, Parent F, et al. Prognostic Value of Follow-Up
- 697 Hemodynamic Variables After Initial Management in Pulmonary Arterial
- 698 Hypertension. *Circulation*. 2018;137:693-704. doi:
- 699 10.1161/CIRCULATIONAHA.117.029254
- 48. Yogeswaran A, Richter MJ, Sommer N, Ghofrani HA, Seeger W, Tello K, Gall
- 701 H. Advanced risk stratification of intermediate risk group in pulmonary
- 702 arterial hypertension. *Pulm Circ*. 2020;10:2045894020961739. doi:
- 703 10.1177/2045894020961739

704	49.	Liu S, Cheng L, Fu Y, Liu BF, Liu X. Characterization of IgG N-glycome
705		profile in colorectal cancer progression by MALDI-TOF-MS. J Proteomics.
706		2018;181:225-237. doi: 10.1016/j.jprot.2018.04.026
707	50.	Pan H, Wu Z, Zhang H, Zhang J, Liu Y, Li Z, Feng W, Wang G, Liu Y, Zhao
708		D, et al. Identification and validation of IgG N-glycosylation biomarkers of
709		esophageal carcinoma. Front Immunol. 2023;14:981861. doi:
710		10.3389/fimmu.2023.981861
711	51.	Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of
712		FcgammaRI in complex with Fc reveals the importance of glycan recognition
713		for high-affinity IgG binding. Proc Natl Acad Sci USA. 2015;112:833-838.
714		doi: 10.1073/pnas.1418812112
715	52.	Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH,
716		Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves
717		binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J
718		Biol Chem. 2002;277:26733-26740. doi: 10.1074/jbc.M202069200
719	53.	Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ.
720		Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17:698-717. doi:
721		10.1038/s41569-020-0381-0
722	54.	Amez Martin M, Wuhrer M, Falck D. Serum and Plasma Immunoglobulin G
723		Fc N-Glycosylation Is Stable during Storage. J Proteome Res. 2021;20:2935-
724		2941. doi: 10.1021/acs.jproteome.1c00148
725	55.	Qin W, Pei H, Qin R, Zhao R, Han J, Zhang Z, Dong K, Ren S, Gu J.

- Alteration of Serum IgG Galactosylation as a Potential Biomarker for 726
- Diagnosis of Neuroblastoma. J Cancer. 2018;9:906-913. doi: 727
- 10.7150/jca.22014 728
- 729

Table 1. Baseline characteristics. 730

	Discovery Cohort (n = 273)	Validation Cohort $(n = 349)$		
Recruitment period	2013-2020	2006-2013		
Age, y	32.8 ± 10.4	35.9 ± 16.8		
Male, n (%)	58 (21.2)	109 (31.2)		
Ethnic origin	Asian	Asian		
IPAH/HPAH, n (%)	259/14 (94.9/5.1)	338/11 (96.8/3.2)		
WHO FC, n (%)				
Ι	7 (2.8)	6 (1.8)		
II	103 (41.2)	107 (32.7)		
III	124 (49.6)	199 (60.9)		
IV	16 (6.4)	15 (4.6)		
6MWD, m	416.8 ± 103.0	377.4 ± 116.7		
NT-proBNP, pg/mL	941.0 (230.5–2,212.0)	881.0 (289.0–1,944.0)		
RAP, mm Hg	8.4 ± 6.0	8.0 ± 5.5		
mPAP, mm Hg	58.8 ± 15.6	61.4 ± 14.6		
PAWP, mm Hg	9.5 ± 2.9	8.3 ± 3.3		
PVR, Wood units	13.2 ± 6.1	15.4 ± 7.8		
Cardiac index, L/min/kg/m ²	2.5 ± 0.7	2.5 ± 0.9		
Cardiac output, L/min	4.2 ± 1.3	4.0 ± 1.5		
SvO ₂ , %	65.5 ± 9.1	62.4 ± 10.8		
Three-strata risk (I/II/III), n (%)	88/138/30 (33.1/55.6/11.3)	96/206/37 (28.5/60.5/11.0)		
Targeted therapy, n (%)				
Treatment naive	11 (4.0)	66 (18.9)		
Monotherapy	80 (29.3)	227 (65.0)		
Dual therapy	148 (54.2)	53 (15.2)		
Triple therapy	34 (12.5)	3 (0.9)		

6MWD = 6-minute walking distance; HPAH = heritable pulmonary arterial 731

- 732 hypertension; IPAH = idiopathic pulmonary arterial hypertension; mPAP = mean
- pulmonary artery pressure; NT-proBNP = N-terminal pro-B-type natriuretic peptide;
- PAWP = pulmonary artery wedge pressure; PVR = pulmonary vascular resistance;
- RAP= right atrial pressure; SvO_2 = mixed venous oxygen saturation; WHO FC = World
- 736 Health Organization functional class.

737 Table 2. Results of Cox proportional hazards models examining the relationship between plasma IgG Fucosylation and risk of all-cause death in

	Unadjusted		Fully-adjuste	d	
	HR (95%CI)	P value	HR (95%CI)	P value	<i>P</i> for interaction
Total $(n = 581)$	0.451 (0.292-0.696)	< 0.001	0.490 (0.315-0.763)	0.002	
Sex					0.748
Male $(n = 155)$	0.332 (0.154-0.715)	0.005	0.387 (0.159-0.941)	0.035	
Female $(n = 426)$	0.510 (0.301-0.863)	0.012	0.527 (0.307-0.906)	0.014	
Therapy					0.410
Treatment naïve and monotherapy $(n = 373)$	0.503 (0.304-0.834)	0.008	0.570 (0.340-0.953)	0.032	
Dual and triple therapy $(n = 208)$	0.340 (0.144-0.805)	0.014	0.376 (0.148-0.954)	0.043	

738 overall analysis and subgroup analyses according to sex and therapeutic strategies.

739 The factors in the fully-adjusted models included age, sex, WHO-FC, 6MWD, NT-proBNP, RAP, SvO₂, PVR, cardiac index, type of PAH, and

therapeutic strategies. The factors in the fully-adjusted models included age, sex, WHO-FC, 6MWD, NT-proBNP, RAP, SvO₂, PVR, cardiac

index, type of PAH, and therapeutic strategies. 6MWD = 6-minute walking distance; NT-proBNP = N-terminal pro-B-type natriuretic peptide;

PAH = pulmonary arterial hypertension. PVR = pulmonary vascular resistance; RAP = right atrial pressure; SvO_2 = mixed venous oxygen

saturation; WHO FC = World Health Organization functional class.

Figures 744



- 746 Figure1. Study design. 6MWD = 6-minute walking distance; NT-proBNP = N-
- terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension. PVR 747
- = pulmonary vascular resistance; RAP = right atrial pressure; ROC = receiver-748
- operating characteristic; $SvO_2 = mixed$ venous oxygen saturation; WHO FC = World 749
- 750 Health Organization functional class.



Figure 2. Hazard ratios and 95% CI from Cox regression analysis evaluating the prognostic IgG N-glycan traits in the discovery and validation

cohorts.



754

Figure 3. Kaplan-Meier survival curve for all-cause death stratified by IgG 755

Fucosylation in patients with pulmonary artery hypertension. "High Fuc" or "Low 756

757 Fuc" represents IgG Fucosylation higher or lower than 0.9741.



758





761 proBNP, RAP, SvO₂, PVR, cardiac index, type of PAH, and therapeutic strategies. 6MWD = 6-minute walking distance; NT-proBNP = N-

762 terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension. PVR = pulmonary vascular resistance; RAP = right atrial

pressure; SvO_2 = mixed venous oxygen saturation; WHO FC = World Health Organization functional class.



Figure 5. The performance of the established three-strata model (from the SPAHR 765

and COMPERA analyses) before and after the addition of IgG Fucosylation evaluated 766

by receiver-operating characteristic analysis. AUC = area under the curve. 767



769 Figure 6. Kaplan-Meier survival curve for all-cause death stratified by the established three-strata model (from the SPAHR and COMPERA

analyses) (A) before and (B) after the addition of IgG Fucosylation in patients with pulmonary artery hypertension.